These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
456 related articles for article (PubMed ID: 23381014)
1. Anti-diabetic medications and the risk of hepatocellular cancer: a systematic review and meta-analysis. Singh S; Singh PP; Singh AG; Murad MH; Sanchez W Am J Gastroenterol; 2013 Jun; 108(6):881-91; quiz 892. PubMed ID: 23381014 [TBL] [Abstract][Full Text] [Related]
2. Anti-diabetic medications and risk of pancreatic cancer in patients with diabetes mellitus: a systematic review and meta-analysis. Singh S; Singh PP; Singh AG; Murad MH; McWilliams RR; Chari ST Am J Gastroenterol; 2013 Apr; 108(4):510-9; quiz 520. PubMed ID: 23399556 [TBL] [Abstract][Full Text] [Related]
3. Anti-diabetic medications do not influence risk of lung cancer in patients with diabetes mellitus: a systematic review and meta-analysis. Nie SP; Chen H; Zhuang MQ; Lu M Asian Pac J Cancer Prev; 2014; 15(16):6863-9. PubMed ID: 25169538 [TBL] [Abstract][Full Text] [Related]
4. Antidiabetic medications and the risk of colorectal cancer in patients with diabetes mellitus: a systematic review and meta-analysis. Singh S; Singh H; Singh PP; Murad MH; Limburg PJ Cancer Epidemiol Biomarkers Prev; 2013 Dec; 22(12):2258-68. PubMed ID: 24042261 [TBL] [Abstract][Full Text] [Related]
6. Antidiabetic Medications and the Risk of Endometrial Cancer in Patients. Tian J; Liang Y; Qu P Gynecol Obstet Invest; 2019; 84(5):455-462. PubMed ID: 30808843 [TBL] [Abstract][Full Text] [Related]
7. Conventional hypoglycaemic agents and the risk of lung cancer in patients with diabetes: a meta-analysis. Wu Y; Liu HB; Shi XF; Song Y PLoS One; 2014; 9(6):e99577. PubMed ID: 24924771 [TBL] [Abstract][Full Text] [Related]
8. Pharmacologic Therapy of Diabetes and Overall Cancer Risk and Mortality: A Meta-Analysis of 265 Studies. Wu L; Zhu J; Prokop LJ; Murad MH Sci Rep; 2015 Jun; 5():10147. PubMed ID: 26076034 [TBL] [Abstract][Full Text] [Related]
9. Metformin and reduced risk of hepatocellular carcinoma in diabetic patients: a meta-analysis. Zhang H; Gao C; Fang L; Zhao HC; Yao SK Scand J Gastroenterol; 2013 Jan; 48(1):78-87. PubMed ID: 23137049 [TBL] [Abstract][Full Text] [Related]
10. Association between hepatocellular carcinoma and type 2 diabetes mellitus in Italy: potential role of insulin. Donadon V; Balbi M; Casarin P; Vario A; Alberti A World J Gastroenterol; 2008 Oct; 14(37):5695-700. PubMed ID: 18837086 [TBL] [Abstract][Full Text] [Related]
11. Meta-analysis: The efficacy of metformin and other anti-hyperglycemic agents in prolonging the survival of hepatocellular carcinoma patients with type 2 diabetes. Zhou J; Ke Y; Lei X; Wu T; Li Y; Bao T; Tang H; Zhang C; Wu X; Wang G; Li J; Zhang H; Ni F; Ye Z; Wang L Ann Hepatol; 2020; 19(3):320-328. PubMed ID: 31980358 [TBL] [Abstract][Full Text] [Related]
12. Thiazolidinediones and Glucagon-Like Peptide-1 Receptor Agonists and the Risk of Nonalcoholic Fatty Liver Disease: A Cohort Study. van Dalem J; Driessen JHM; Burden AM; Stehouwer CDA; Klungel OH; de Vries F; Brouwers MCGJ Hepatology; 2021 Nov; 74(5):2467-2477. PubMed ID: 34129693 [TBL] [Abstract][Full Text] [Related]
13. Risk of hepatocellular carcinoma in diabetic patients and risk reduction associated with anti-diabetic therapy: a population-based cohort study. Lai SW; Chen PC; Liao KF; Muo CH; Lin CC; Sung FC Am J Gastroenterol; 2012 Jan; 107(1):46-52. PubMed ID: 22085817 [TBL] [Abstract][Full Text] [Related]
14. Monotherapy with Metformin versus Sulfonylureas and Risk of Cancer in Type 2 Diabetic Patients: A Systematic Review and Meta-Analysis. Mekuria AN; Ayele Y; Tola A; Mishore KM J Diabetes Res; 2019; 2019():7676909. PubMed ID: 31828167 [TBL] [Abstract][Full Text] [Related]
15. Hypoglycemic agents and incidence of pancreatic cancer in diabetic patients: a meta-analysis. Zhao Z; He X; Sun Y Front Pharmacol; 2023; 14():1193610. PubMed ID: 37497113 [No Abstract] [Full Text] [Related]
16. Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease. Donadon V; Balbi M; Mas MD; Casarin P; Zanette G Liver Int; 2010 May; 30(5):750-8. PubMed ID: 20331505 [TBL] [Abstract][Full Text] [Related]
17. Effect of hypoglycemic agents on survival outcomes of lung cancer patients with diabetes mellitus: A meta-analysis. Xin WX; Fang L; Fang QL; Zheng XW; Ding HY; Huang P Medicine (Baltimore); 2018 Mar; 97(9):e0035. PubMed ID: 29489653 [TBL] [Abstract][Full Text] [Related]
18. Cardiovascular risk associated with the use of glitazones, metformin and sufonylureas: meta-analysis of published observational studies. Pladevall M; Riera-Guardia N; Margulis AV; Varas-Lorenzo C; Calingaert B; Perez-Gutthann S BMC Cardiovasc Disord; 2016 Jan; 16():14. PubMed ID: 26769243 [TBL] [Abstract][Full Text] [Related]
19. Effect of statin on hepatocellular carcinoma in patients with type 2 diabetes: A nationwide nested case-control study. Kim G; Jang SY; Han E; Lee YH; Park SY; Nam CM; Kang ES Int J Cancer; 2017 Feb; 140(4):798-806. PubMed ID: 27861855 [TBL] [Abstract][Full Text] [Related]
20. Metformin in the prevention of hepatocellular carcinoma in diabetic patients: A systematic review. Cunha V; Cotrim HP; Rocha R; Carvalho K; Lins-Kusterer L Ann Hepatol; 2020; 19(3):232-237. PubMed ID: 31836424 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]